Miguel-Blanco, Celia
Murithi, James M.
Benavente, Ernest Diez
Angrisano, Fiona
Sala, Katarzyna A.
van Schalkwyk, Donelly A.
Vanaerschot, Manu
Schwach, Frank
Fuchter, Matthew J.
Billker, Oliver
Sutherland, Colin J.
Campino, Susana G.
Clark, Taane G.
Blagborough, Andrew M.
Fidock, David A.
Herreros, Esperanza
Gamo, Francisco Javier
Baum, Jake
Delves, Michael J.
Funding for this research was provided by:
Bill and Melinda Gates Foundation (OPP1043501, Malaria Drug Accelerator Consortium, OPP1043501)
Medicines for Malaria Venture (RD/15/0017, MMV08/2800)
Wellcome Trust (206194/Z/17/Z, 100993/Z/13/Z, ISSF fund)
Public Health England
European Developing Countries Trials Platform
Research England (BloomsburySET)
Medical Research Council (MR/M01360X/1, MR/N00227X/1)
Biotechnology and Biological Sciences Research Council (BB/R013063/1)
Isaac Newton Trust
Alborada Fund
University of Cambridge (JRG Scheme)
Global Health Innovative Technology Fund
Royal Society
Article History
Received: 23 November 2020
Accepted: 18 December 2020
First Online: 21 January 2021
Competing interests
: The authors declare no competing interests.